EFFECT OF OLEANANE TRITERPENOID DERIVATIVES ON MONOCYTES

Objective. To study the effect of gem-nitrochloro derivatives of oleanane triterpenoids on the cell viability of human monocytes. Material and methods. In the course of standard experiments to assess cell viability using the Alamar Blue reagent and the Tecan Spark 10M plate reader, the cytotoxic activity of semisynthetic triterpenoids was analyzed against human monocytes in the range of effective concentrations of 10-0.001 μM.

Results. The experimental study showed that at concentrations of 10-0.001 μM, the test compounds do not cause cell death and have virtually no effect on the viability of monocytes. At the same time, the 3R-nitrochloro derivative based on oleanolic acid showed the maximum effect of stimulating cell proliferation at a concentration of 1 μM, resulting in an increase in their viability under experimental conditions. In this case, a concentration range of 10-0.001 μM was determined, in which there was no cytotoxic effect. This range is wide for representatives of this class of substances and exceeds that of the known anti-inflammatory agents such as methyl bardoxolone and omaveloxolone, which exhibit their protective effect only in nM concentrations, and at μM concentrations they have cytotoxicity.

Conclusion. Based on the conducted study, it can be concluded that there is no cytotoxicity of gem-nitrochloro derivatives of triterpenoids against human monocytes. The data obtained also indicate their suitability for further study as protective agents for combating inflammatory reactions.

1. Farmakologicheskie svojstva polusinteticheskih proizvodnyh diterpenoidov I pentaciklicheskih triterpenoidov protiv kletochnyh linij raka predstatel'noj zhelezy dlya analiza harakteristik «struktura-aktivnost'« (Pharmacological properties of semisynthetic diterpenoid and pentacyclic triterpenoid derivatives against prostate cancer cell lines for structure-activity profile analysis): baza dannyh № 2024626159 Ros. Federacija; zajavl. 29.11.2024; opubl. 19.12.2024. Bjul. № 12 (In Russ).

2. Farmakologicheskie svojstva polusinteticheskih proizvodnyh pentaciklicheskih triterpenoidov dlya analiza citotoksichnosti i immunosovmestimosti (Pharmacological properties of semisynthetic derivatives of pentacyclic triterpenoids for cytotoxicity immunocompatibility analysis): bazadannyh № 2024626061 Ros. Federaciya; zayavl. 04.12.2024; opubl. 17.12.2024. Byul. № 12. (In Russ).

3. De Zeeuw D. [et al.] Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New England Journal of Medicine. 2013; 369(26): 2492-2503. (in Engl)

4. Meng X. [et al.] CDDO-imidazolide targets multiple amino acid residues on the Nrf2 adaptor, Keap1. Journal of Medicinal Chemistry. 2020; 63(17): 9965-9976. (in Engl)

5. Dinkova-Kostova A.T., Copple I.M. Advances and challenges in therapeutic targeting of NRF2. Trends in pharmacological sciences. 2023; 44(3): 137-149. (in Engl)

6. Liby K.T., Sporn M.B., Esbenshade T.A. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacological reviews. 2012; 64(4): 972-1003. (in Engl)

7. Sporn M.B. [et al.] New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. Journal of Natural Products. 2011; 74(3): 537-545. (in Engl)

8. Pallesen J.S., Tran K.T., Bach A. Non-covalent small-molecule Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) inhibitors and their potential for targeting central nervous system diseases. Journal of Medicinal Chemistry. 2018; 61(18): 8088-8103. (in Engl)

9. Pilotto F., Chellapandi D.M., Puccio H. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. Trends in Molecular Medicine. 2024; 30(2): 117-125. (in Engl)

10. Cuadrado A. [et al.] Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nature Reviews Drug Discovery. 2019; 18(4): 295-317. (in Engl)